Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure

a human g protein and receptor technology, applied in the field of human g protein-coupled receptors and modulators thereof for the treatment of ischemic heart disease and congestive heart failure, can solve the problems of not being able to directly activate survival pathways or inhibit cardiac myocyte death drugs currently available in the clinic, and achieve the effect of reducing cardiac output and increasing venous pressur

Inactive Publication Date: 2007-09-27
ARENA PHARMA
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

Overexpression of RUP41 promotes cardiomyocyte survival and reduces apoptosis, suggesting that modulators of RUP41 can effectively treat ischemic heart disease and congestive heart failure by inhibiting cardiomyocyte death and enhancing cardiac function.

Problems solved by technology

However, there are no drugs currently available in the clinic designed to inhibit cardiac myocyte death or directly activate survival pathways.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
  • Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
  • Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure

Examples

Experimental program
Comparison scheme
Effect test

example 1

Full-Length Cloning of Endogenous Human RUP41

[0584] The disclosed human RUP41 was identified based upon the use of the GenBank database information. While searching the database, a cDNA clone with Accession Number U66581 was identified as a human genomic sequence from chromosome 7. The fall length RUP41 was cloned by PCR using primers:

5′-TCCCCCGGGAAAAAAACCAACTGCTGCAAA-3′(SEQ ID NO:7; sense),5′-TAGGATCCATTTGAATGTGGATTTGGTGAAA-3′(SEQ ID NO:8; antisense, containing a BamHI site)

and human genomic DNA as template. Amplification was carried out using rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 mM of each primer, and 0.2 mM of each 4 nucleotides. The cycle condition was 30 cycles of 94° C. for 1 min, 50° C. for 1 min and 72° C. for 1.5 min. The 5′ PCR primer was kinased and the 1.38 kb PCR fragment was digested with BamHI and cloned into EcoRV-BamHI site of pCMV expression vector. See, SEQ ID NO:1 for nucleic acid sequence and SEQ ID NO:2 fo...

example 2

Preparation of Non-Endogenous, Constitutively Activated Human RUP41

[0585] Those skilled in the art are credited with the ability to select techniques for mutation of a nucleic acid sequence. Presented below are approaches utilized to create non-endogenous versions of human GPCRs. The mutation disclosed below for RUP41 is based upon an algorithmic approach whereby the 16th amino acid (located in the IC3 region of the GPCR) from a conserved proline (or an endogenous, conservative substitution therefor) residue (located in the TM6 region of the GPCR, near the TM6 / IC3 interface) is mutated, preferably to an alanine, histidine, arginine or lysine amino acid residue, most preferably to a lysine amino acid residue.

[0586] Non-endogenous, constitutively activated full-length human RUP41 is accomplished by mutation of the phenylalanine residue at amino acid position 312 of SEQ ID NO:2 or SEQ ID NO:3 to lysine (F312K).

[0587] 1. Transformer Site-Directed™ Mutagenesis

[0588] Preparation of n...

example 3

Receptor Expression

[0591] Although a variety of cells are available to the art for the expression of proteins, it is most preferred that mammalian cells or melanophores be utilized. The primary reason for this is predicated upon practicalities, i.e., utilization of, e.g., yeast cells for the expression of a GPCR, while possible, introduces into the protocol a non-mammalian cell which may not (indeed, in the case of yeast, does not) include the receptor-coupling, genetic-mechanism and secretary pathways that have evolved for mammalian systems—thus, results obtained in non-mammalian cells, while of potential use, are not as preferred as that obtained from mammalian cells or melanophores. Of the mammalian cells, CHO, COS-7, 293 and 293T cells are particularly preferred, although the specific mammalian cell utilized can be predicated upon the particular needs of the artisan. See infra as relates to melanophores, including Example 8.

[0592] a. Transient Transfection

[0593] On day one, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
dissociation constantaaaaaaaaaa
dissociation constantaaaaaaaaaa
dissociation constantaaaaaaaaaa
Login to View More

Abstract

The present invention relates to methods of identifying whether a candidate compound is a modulator of an orphan G protein-coupled receptor (GPCR). Preferably the GPCR is human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In some embodiments, overexpression of the GPCR promotes survival of cardiomyocytes. In some embodiments, overexpression of the GPCR rescues cardiomyoctes from hypoxia / reoxygenation induced apoptosis. In some embodiments, the GPCR is down-regulated in individuals with congestive heart failure. Agonists of the invention are envisioned to be useful as therapeutic agents for the treatment of ischemic heart disease, including myocardial infarction, post-myocardial infarction remodeling, and congestive heart failure.

Description

[0001] This patent application claims the benefit of priority from the following provisional application, filed via U.S. Express mail with the United States Patent and Trademark Office on the indicated date: U.S. Provisional No. 60 / 400,774, filed Aug. 1, 2002. The foregoing application is incorporated by reference herein in its entirety.FIELD OF THE INVENTION [0002] The present invention relates to methods of identifying whether a candidate compound is a modulator of an orphan G protein-coupled receptor (GPCR). Preferably the GPCR is human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In some embodiments, overexpression of the GPCR promotes survival of cardiomyocytes. In some embodiments, overexpression of the GPCR rescues cardiomyocytes from hypoxia / reoxygenation induced apoptosis. In some embodiments, the GPCR is down-regulated in individuals with congestive hea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K49/00A01K67/027C12N5/10G01N33/53G01N33/567G01N33/569A61K38/17A61K45/00A61K51/00A61K51/08A61P9/04A61P9/10A61P43/00C07K14/705C07K19/00C12N1/15C12N1/19C12N1/21C12N9/14C12N15/09C12Q1/02C12Q1/68G01N33/74
CPCA01K2217/05A01K2217/075A01K2267/03G01N2500/04G01N33/74G01N2333/726C07K14/705A61P43/00A61P9/00A61P9/04A61P9/10A61P9/14
Inventor ADAMS, JOHN W.CONNOLLY, DANIEL T.
Owner ARENA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com